Joint Formulary & PAD

Aripiprazole - Bipolar disorder (adolescents)

You are here : Home > Formulary Search > Aripiprazole - Bipolar disorder (adolescents)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Oral solution
  • Oro-dispersible tablets
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :

Documentation

NICE Technology Appraisal
NICE TA292 Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder

PAD Profile

ChemicalSubstance :
Aripiprazole
Indication :
Bipolar disorder (adolescents)
Group Name :
Keywords :
NICE, manic episodes, mania, antipsychotics
Brand Names Include :
Abilify
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

25 Sep 13 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The network noted that NICE TA 292 recommends aripiprazole as a possible treatment (for up to 12 weeks) for moderate to severe manic episodes in young people aged 13 and older with bipolar I disorder. It concurred that as treatment is limited to 12 weeks, prescribing for this indication should remain with Surrey & Borders Partnership Foundation Trust.

Other Indications

Below are listed other indications that Aripiprazole is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Bipolar disorder (adolescents).

  • No records returned.